Claims for Patent: 10,034,931
✉ Email this page to a colleague
Summary for Patent: 10,034,931
| Title: | Use of EGFR pathway inhibitors to increase immune responses to antigens |
| Abstract: | This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis. |
| Inventor(s): | Pollack Brian P., Compans Richard W., Pulit-Penaloza Joanna A., Skountzou Ioanna |
| Assignee: | Emory University |
| Application Number: | US15024102 |
| Patent Claims: |
Details for Patent 10,034,931
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | FLUARIX, FLUARIX QUADRIVALENT | influenza vaccine | Injection | 125127 | August 31, 2005 | 10,034,931 | 2034-09-23 |
| Glaxosmithkline Biologicals | FLUARIX, FLUARIX QUADRIVALENT | influenza vaccine | Injection | 125127 | December 14, 2012 | 10,034,931 | 2034-09-23 |
| Id Biomedical Corporation Of Quebec | FLULAVAL, FLULAVAL QUADRIVALENT | influenza vaccine | Injection | 125163 | October 05, 2006 | 10,034,931 | 2034-09-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 3 of 3 entries
